Advertisement

Topics

Vycellix and Moffitt Cancer Center Announce a Collaborative Research Study to Evaluate Novel Product Candidates for Improving Adoptive Cell Immunotherapies for Cancer

09:11 EST 27 Feb 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Studies designed to enhance T cell and NK cell potencies through improved genetic modification and increased cytolytic granules Vycellix, Inc., a biopharmaceutical company advancing innovative small molecules to enhance cell...

Other Sources for this Article

Vycellix, Inc.
Douglas W. Calder, 772-418-6302
President
dcalder@vycellix.com

NEXT ARTICLE

More From BioPortfolio on "Vycellix and Moffitt Cancer Center Announce a Collaborative Research Study to Evaluate Novel Product Candidates for Improving Adoptive Cell Immunotherapies for Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...